ultricies, sapien non vulputate facilisis, purus diam tincidunt nisl, quis consectetur nibh est ornare nisl. Vivamus feugiat ultrices elit, a ultrices mauris mollis eget. Donec nulla odio, tempus vel sagittis ac, euismod quis augue. Sed venenatis tortor in mauris feugiat, eget faucibus ligula aliquet. Phasellus et sem a justo dignissim consectetur. Nullam venenatis erat id commodo porta. Integer in nibh sit amet nunc malesuada mattis. Praesent ut risus elit. Aenean pellentesque ligula eget est volutpat, nec convallis arcu dignissim. Duis nisl sapien, accumsan sed lorem nec, vulputate volutpat ante. Donec tincidunt tempus metus, id scelerisque massa convallis placerat.
Etiam lacinia aliquam odio, ut vestibulum libero porta non. Duis tincidunt pretium diam at bibendum. Suspendisse consectetur aliquam lorem at lobortis. Aenean auctor neque justo, ac vehicula risus sollicitudin eget. In tempus erat eu lectus dignissim, gravida imperdiet dolor dignissim. Mauris pulvinar suscipit purus in dictum. Curabitur quis dui nec sem ullamcorper pretium. Proin in purus in eros interdum dictum sed quis mauris. Praesent sapien sapien, ultricies in mattis sit amet, aliquet eget nulla. Nunc ante velit, pharetra eget dui eu, facilisis adipiscing risus. Donec nisi leo, convallis ut ultricies accumsan, placerat eget libero. Curabitur blandit feugiat est, ultrices porttitor enim molestie vitae. Curabitur fringilla felis et turpis tempor aliquam.
LONDON, Sept 28 (Reuters) - Philip Morris International (PMI) on Thursday signalled
posted by iqos i one Martes, 10 Diciembre 2024 14:05 Comment Linka slower than anticipated U.S. roll out of its IQOS heated tobacco device, a
choice analysts said was positive for its competitors in the short term.
The New York-listed Marlboro maker also said it aims for more than two thirds of its
net revenues to come from "smoke-free" products by 2030, up
from 50% in 2025, as it tries to transform its image from a cigarette purveyor to a driver of the shift to healthier
alternatives.
Investors have been closely watching IQOS' entry into the U.S.,
the world's largest market for nicotine products, and had
been expecting it from May 2024 next year. Reuters reported on Wednesday that PMI is hiring lobbyists across a host of key U.S.
states ahead of the launch.
Chief Executive Jacek Olczak said IQOS would
launch in four cities in two unnamed U.S. states from 2024, but a national launch
would only come after PMI receives approval to sell the latest version, known as IQOS ILUMA.
The company was planning to apply for approval in October and expected it from 2025, he continued.
"We need to warm up the tyres," he said of the initial launch, which would help PMI fine tune its approach.
A national roll-out of ILUMA would follow but
in phases, he continued, adding launching in 10 states in the first year would make sense.
Meaningful traction for PMI's heated tobacco products in the U.S.
"now looks delayed until ILUMA," Owen Bennett, equity analyst at Jefferies, said in a note, adding this was
a positive for PMI's rivals.
Olczak also signalled that PMI's push into non-nicotine products was no longer a
priority. It recently scrapped an ambition for $1 billion in net revenues
to come from sales of such products by 2025.
Instead, PMI will focus its resources on IQOS and nicotine pouch
brand ZYN, Olczak said, adding it had been too optimistic around acceptance of big tobacco companies operating outside of nicotine.
PMI also announced updated medium-term targets including for revenue and earnings per share, and ambitious
volume targets for IQOS and ZYN.
ZYN and other oral nicotine products in the U.S.
would help drive an expected $2 billion in revenues there in 2024,
even before IQOS ILUMA, executives said.
PMI shares were up 1.5% on Thursday. (Reporting by
Emma Rumney in London and Granth Vanaik in Bengaluru;
additional reporting by Ananya Mariam Rajesh in Bengaluru; Writing by Emma
Rumney; Editing by Elaine Hardcastle and Josie Kao)